NADIA: Wk 96 Results With DTG vs DRV/RTV and TDF vs ZDV as Second-line ART in Africa

February 13-16, 2022; Virtual
This trial supports use of DTG + 2 NRTIs as second-line ART, even if NRTIs are predicted to have no activity, but resistance is a concern.
Format: Microsoft PowerPoint (.ppt)
File Size: 502 KB
Released: February 18, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Cepheid
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck & Co., Inc.
ViiV Healthcare

Related Content

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 30, 2022

Clinical Care Options (CCO) expert analysis of new data from IDWeek and HIV Glasgow 2022, provided by expert HIV faculty

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Released: November 30, 2022

European pioneers discuss the latest data and guideline recommendations for implementing LA ART into practice, from Clinical Care Options (CCO)

Celia Jonsson-Oldenbuettel, MD, PhD
Program Director
person default Tom Stephane De Wit, MD, PhD Eric Florence, MD, PhD Mireia SantaCreu Guerrero, MSN person default Laurence Slama, MD, PhD
Released: November 29, 2022

Dr Colleen Kelley discusses key advances in HIV prevention over the past year, from Clinical Care Options (CCO)

Colleen Kelley, MD, MPH Released: November 29, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings